Holger Thurm

Holger Thurm, MD, MSc, is an Executive Director at Pfizer, where they lead the clinical development of innovative cancer therapies. With 20 years of experience in the healthcare industry, Holger has played a critical role in the regulatory filing and approval of several breakthrough drugs, including Lorbrena/Lorviqua®, Xalkori®, and Gliolan®. They previously held positions as a Medical Director at Genentech and as a Project Manager in Clinical Research at medac GmbH. Holger earned an MD and an MS in molecular medicine and biology from Freie Universität Berlin, and is recognized as an expert in lung cancer. Their mission focuses on improving the lives of patients with malignancies and advancing the science of oncology.